Skip to content

Multi-gene Methylation Kit for Plasma Samples to Assist in the Diagnosis of Colorectal Cancer: A Multi-center Clinical Study

Multi-gene Methylation Kit for Plasma Samples to Assist in the Diagnosis of Colorectal Cancer: A Multi-center Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092332
Enrollment
Unknown
Registered
2024-11-14
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Colorectal cancer :None
patient
Health, Benign disease patient group:None

Sponsors

Zhujiang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. No history of previous tumors; 2.Age between 18 and 75 years; 3. Male or non-pregnant, non-lactating female; 4.No prior radiotherapy or chemotherapy before enrollment; 5.Able to provide sufficient and qualified blood samples; 6.Voluntary signature of informed consent. For the Colorectal Cancer Group: 7.Preoperative colonoscopy pathology diagnosis of colorectal adenocarcinoma or high-grade adenoma. For the Control Group: 8.Some with certain gastrointestinal symptoms, with a recommendation for colonoscopy; colonoscopy pathology diagnosis of benign gastrointestinal diseases; 9.Some healthy individuals with no significant findings in colonoscopy pathology; 10.Other confirmed tumors unrelated to colorectal cancer, including gastric cancer, liver cancer, esophageal cancer, biliary cancer, pancreatic cancer, as well as common non-digestive system tumors such as lung cancer, breast cancer, cervical cancer, and thyroid cancer.

Exclusion criteria

Exclusion criteria: 1.Plasma contamination in the laboratory; 2.Participation in another clinical trial within 30 days before enrollment; 3.Pregnant or lactating women; 4.History of tumors and corresponding tumor treatments; 5.Blood transfusion within 30 days before blood collection; 6.History of organ, bone marrow, or stem cell transplantation; 7.Health conditions unsuitable for blood collection; 8.Incomplete clinical data (including TNM staging, tumor volume, pathological classification, site of occurrence, vascular invasion, age, sex, depth of invasion, degree of differentiation, alcohol history, smoking history, etc.); 9.Other conditions deemed unsuitable for the study by the researchers

Design outcomes

Primary

MeasureTime frame
Methylation level;

Countries

China

Contacts

Public ContactCui Chunhui

Zhujiang Hospital, Southern Medical University

drcuich@163.com+86 135 7054 1388

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026